Blog
Driving Better Outcomes with Digital Therapeutics
Share on
We’re living in a time where healthcare is no longer limited by physical boundaries. Thanks to the rapid rise of digital therapeutics solutions, the industry is undergoing a massive transformation—one where treatments are increasingly software-driven, deeply personalized, and designed to empower both patients and providers.
It’s no surprise then that the digital therapeutics industry is booming. As we look around, it’s clear this isn’t just a trend—it’s the future of healthcare.
Digital therapeutics (DTx) are clinically validated, software-based interventions that help prevent, manage, or treat a range of medical conditions. Unlike generic wellness apps, DTx products are evidence-based, regulated, and often eligible for insurance reimbursement.
The benefits of digital therapeutics go well beyond convenience. They offer:
For patients, it means more accessible, data-driven care. For healthcare providers, it’s a powerful way to improve outcomes while lowering costs. And for pharma companies, it opens up new avenues to create differentiated offerings that go beyond the pill.
In short, the digital therapeutics industry is reshaping the future of care delivery, faster than many expected.
The global digital therapeutics market was valued at $7.67 billion in 2024 and is projected to reach $32.5 billion by 2030, growing at a CAGR of 27.77% from 2025 to 2030.
That growth is driven by a mix of factors:
These digital therapeutics trends are shaping how pharma approaches innovation, compliance, and patient engagement in a hybrid care world.
Traditionally, pharma companies have focused on drug development pipelines. But with growing pressure to deliver value beyond the product, the relationship between digital therapeutics and pharma is getting a major upgrade.
We’re seeing more strategic collaborations, such as:
These are more than one-off experiments—they represent a shift in mindset, where pharma companies view digital therapeutics as a core component of future care models.
And let’s be real: patients are ready. They want better engagement, faster feedback, and more personalized care. Digital therapeutics are helping pharma deliver just that.
DTx isn’t a one-size-fits-all approach. Its strength lies in adaptability. Let’s break down some of the most compelling digital therapeutics use cases we’re seeing today:
Poor adherence costs the healthcare system between $100–$300 billion a year. Digital therapeutics can curb this through personalized nudges, reminders, and coaching—all delivered via mobile or wearable devices.
With rising rates of depression, anxiety, and substance abuse, there’s an urgent need for scalable, affordable support. FDA-approved apps like reSET show that digital interventions can deliver real outcomes for behavioral health.
VR-powered platforms are helping patients manage preoperative anxiety and post-op pain by creating immersive, calming environments, reducing reliance on opioids.
AR/VR tools are now being used to train surgeons and help patients visualize their treatment plans, increasing trust and compliance.
The digital therapeutics space isn’t being led by pharma alone. Startups and tech giants are equally influential in shaping the future.
These players are leveraging data, design thinking, and scale to create digital therapeutics solutions that are agile, impactful, and patient-centric.
The digital therapeutics industry thrives on collaboration. No one player can do it all.
Pharma companies bring R&D expertise and regulatory knowledge. Tech firms bring UX design, AI capabilities, and speed. Together, they can build, launch, and scale digital therapeutics that are both clinically effective and user-friendly.
At Hexaware, we believe the future of healthcare lies in creating smarter, faster, and more human-centered experiences.
Our role? To help life sciences companies like yours turn digital therapeutics from ideas into impact.
Here’s what that looks like:
We use our human-centered design frameworks to create intuitive, inclusive DTx products that truly support behavior change and drive measurable outcomes.
With pre-built accelerators, validation tools, and agile delivery models, we help you build, test, and launch DTx solutions—fast.
From digital marketing ops to performance analytics, we offer tools that help you refine your go-to-market strategy and learn from every interaction.
We’ve got strong alliances with cloud providers, data platforms, and compliance partners to ensure your solution is scalable and secure.
We help you understand the commercial opportunity, design value-based reimbursement models, and ensure payer alignment from the start.
In other words, we’re not just here to build software; we’re here to help you build a sustainable, high-impact digital therapeutics business.
Digital therapeutics is a revolution in how we treat, manage, and prevent disease.
Whether you’re launching your first DTx solution or scaling a global portfolio, now’s the time to act. The tools are ready. The market’s primed. And patients are already expecting more.
With Hexaware’s deep life sciences expertise and cutting-edge IT solutions for healthcare, we’ll help you deliver better care outcomes, accelerate innovation, and future-proof your business.
Let’s create the future of healthcare—together. Contact us now!
Hexaware’s role in digital therapeutics (DTx) involves enabling life sciences and healthcare organizations to accelerate innovation, improve patient outcomes, and streamline operations. Key capabilities include:
The future of digital therapeutics (DTx) is defined by rapid growth, regulatory evolution, and deeper integration into mainstream healthcare. Key trends include:
Pharmaceutical companies use digital therapeutics (DTx) to enhance treatment outcomes, improve patient engagement, and optimize clinical operations. Key strategies include: